Abstract
Autologous haematopoietic stem cell transplantation (AHSCT) is now an integral part of the treatment of high-risk solid tumours in children. However, specific characteristics and problems related to paediatric patients must be taken into account. Considering these tumours are rare, indications, efficacy and practical issues of autologous transplantation have been a topic of research and discussion
Highlights
High-dose chemotherapy (HDC) with autologous haematopoietic stem cell transplantation (AHSCT) is becoming a preferred treatment of unfavourable high-risk solid tumours in children
For other tumour patients and patients in partial remission before the transplantation, survival may be increased by introducing double Autologous haematopoietic stem cell transplantation (AHSCT) with post-transplant immunomodulatory therapy
Patients We analysed a total of 46 children with high-risk solid tumours and lymphomas who were treated with high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation at the Department of Haematology and Oncology, Children's Hospital Zagreb between December 2005 and December 2012
Summary
High-dose chemotherapy (HDC) with autologous haematopoietic stem cell transplantation (AHSCT) is becoming a preferred treatment of unfavourable high-risk solid tumours in children. Malignant tumours that require AHSCT treatment are considered rare These can be lymphomas or solid tumours such as neuroblastomas, Ewing’s sarcomas/primitive neuroectodermal tumours (PNET), rhabdomyosarcomas, nephroblastomas, brain tumours and germ-cell tumours [1,2,3,4]. There is a high correlation between chemotherapy dose increase and favourable treatment response in most childhood tumours. Autologous haematopoietic stem cell transplantation (AHSCT) is an integral part of the treatment of high-risk solid tumours in children. Specific characteristics and problems related to paediatric patients must be taken into account. Considering these tumours are rare, indications, efficacy and practical issues of autologous transplantation have been a topic of research and discussion
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Hematology & Thromboembolic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
